share_log

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Shah Prem S

CVS Health | 4: Statement of changes in beneficial ownership of securities-Officer Shah Prem S

西維斯健康 | 4:持股變動聲明-高管 Shah Prem S
美股SEC公告 ·  12/04 06:17

牛牛AI助理已提取核心訊息

Shah Prem S, EVP and Group President of CVS Health, completed a stock transaction on 11/30/2024. The transaction involved the sale of common stock, restricted common stock, ESOP common stock, and deferred stock units. Following the transaction, Shah Prem S holds 42,343.677 shares of common stock, 37,057 shares of restricted common stock, 4,968.7985 shares of ESOP common stock, and 3,468.315 deferred stock units. All shares are held directly. This transaction reflects a strategic decision by the executive, impacting his overall shareholding in CVS Health. Investors may consider this action when evaluating the company's stock performance and executive confidence in the company's future prospects.
Shah Prem S, EVP and Group President of CVS Health, completed a stock transaction on 11/30/2024. The transaction involved the sale of common stock, restricted common stock, ESOP common stock, and deferred stock units. Following the transaction, Shah Prem S holds 42,343.677 shares of common stock, 37,057 shares of restricted common stock, 4,968.7985 shares of ESOP common stock, and 3,468.315 deferred stock units. All shares are held directly. This transaction reflects a strategic decision by the executive, impacting his overall shareholding in CVS Health. Investors may consider this action when evaluating the company's stock performance and executive confidence in the company's future prospects.
CVS Health執行副總裁兼集團總裁Shah Prem S於2024年11月30日完成了股票交易。該交易涉及普通股、限制性普通股、ESOP普通股和遞延股票單位的出售。 交易完成後,Shah Prem S持有42,343.677股普通股、37,057股限制性普通股、4,968.7985股ESOP普通股和3,468.315股遞延股票單位。所有股份均直接持有。 該交易反映了該高管的戰略決策,影響了他在CVS Health的總股權。投資者在評估公司的股票表現和高管對公司未來前景的信心時可以考慮這一行動。
CVS Health執行副總裁兼集團總裁Shah Prem S於2024年11月30日完成了股票交易。該交易涉及普通股、限制性普通股、ESOP普通股和遞延股票單位的出售。 交易完成後,Shah Prem S持有42,343.677股普通股、37,057股限制性普通股、4,968.7985股ESOP普通股和3,468.315股遞延股票單位。所有股份均直接持有。 該交易反映了該高管的戰略決策,影響了他在CVS Health的總股權。投資者在評估公司的股票表現和高管對公司未來前景的信心時可以考慮這一行動。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。